WO2000021548A3 - Angiogenically effective unit dose of fgf and method of administering - Google Patents
Angiogenically effective unit dose of fgf and method of administering Download PDFInfo
- Publication number
- WO2000021548A3 WO2000021548A3 PCT/US1999/022936 US9922936W WO0021548A3 WO 2000021548 A3 WO2000021548 A3 WO 2000021548A3 US 9922936 W US9922936 W US 9922936W WO 0021548 A3 WO0021548 A3 WO 0021548A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fgf
- angiogenically
- mutein
- active fragment
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99951728A EP1121141A2 (en) | 1998-10-13 | 1999-10-13 | Angiogenically effective unit dose of fgf and method of administering |
AU64111/99A AU6411199A (en) | 1998-10-13 | 1999-10-13 | Angiogenically effective unit dose of fgf and method of administering |
JP2000575522A JP2002527401A (en) | 1998-10-13 | 1999-10-13 | Angiogenically effective unit dose of FGF and method of administration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10410398P | 1998-10-13 | 1998-10-13 | |
US60/104,103 | 1998-10-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000021548A2 WO2000021548A2 (en) | 2000-04-20 |
WO2000021548A3 true WO2000021548A3 (en) | 2000-08-31 |
Family
ID=22298692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/022936 WO2000021548A2 (en) | 1998-10-13 | 1999-10-13 | Angiogenically effective unit dose of fgf and method of administering |
Country Status (5)
Country | Link |
---|---|
US (4) | US6451303B1 (en) |
EP (1) | EP1121141A2 (en) |
JP (3) | JP2002527401A (en) |
AU (1) | AU6411199A (en) |
WO (1) | WO2000021548A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002527401A (en) * | 1998-10-13 | 2002-08-27 | カイロン コーポレイション | Angiogenically effective unit dose of FGF and method of administration |
US20030166550A1 (en) | 1999-08-27 | 2003-09-04 | Chiron Corporation | Angiogenically effective unit dose of FGF-2 and method of use |
US8618052B2 (en) | 1998-10-13 | 2013-12-31 | Novartis Vaccines And Diagnostics, Inc. | Method of treating coronary artery disease by administering FGF-5 |
US6992066B2 (en) * | 1998-10-16 | 2006-01-31 | Zimmer Orthobiologics, Inc. | Povidone-containing carriers for polypeptide growth factors |
US7087577B2 (en) * | 1998-10-16 | 2006-08-08 | Zimmer Orthobiologies, Inc. | Method of promoting natural bypass |
AU6634400A (en) * | 1999-08-13 | 2001-03-13 | Chiron Corporation | Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
US20040097996A1 (en) | 1999-10-05 | 2004-05-20 | Omnisonics Medical Technologies, Inc. | Apparatus and method of removing occlusions using an ultrasonic medical device operating in a transverse mode |
US20020115603A1 (en) * | 2000-06-22 | 2002-08-22 | Chiron Corporation | Methods and compositions for the treatment of peripheral artery disease |
AU2001286996A1 (en) * | 2000-08-31 | 2002-03-13 | Chiron Corporation | Stabilized fgf formulations containing reducing agents |
JP2005503120A (en) * | 2001-03-27 | 2005-02-03 | マサチューセッツ インスティテュート オブ テクノロジー | Methods and products for FGF dimerization |
US20030139333A1 (en) * | 2002-01-18 | 2003-07-24 | Genetix Pharmaceuticals, Inc. | Methods and compositions for promoting angiogenesis |
EP1558282A4 (en) * | 2002-10-01 | 2006-04-19 | Chiron Corp | Anti-cancer and anti-infectious disease compositions and methods for using same |
US7195598B2 (en) * | 2003-05-23 | 2007-03-27 | Siemens Aktiengesellschaft | Method for determining the effectiveness of a medical therapy by analysis of collateral vessels |
US7794414B2 (en) | 2004-02-09 | 2010-09-14 | Emigrant Bank, N.A. | Apparatus and method for an ultrasonic medical device operating in torsional and transverse modes |
EP1827472A4 (en) * | 2004-12-06 | 2012-09-05 | Univ California | Methods for improving the structure and function of arterioles |
JP5058822B2 (en) * | 2005-01-25 | 2012-10-24 | ファイブ プライム セラピューティクス, インコーポレイテッド | Compositions and methods for treating cardiac conditions |
EP2155236A1 (en) * | 2007-04-10 | 2010-02-24 | The Board of Regents,The University of Texas System | Combination therapy for cardiac revascularization and cardiac repair |
WO2009142679A2 (en) * | 2008-03-26 | 2009-11-26 | Orthologic Corp. | Methods for treating acute myocardial infarction |
US8623820B2 (en) | 2008-05-02 | 2014-01-07 | University Of Western Ontario | FGF-9 and its use relating to blood vessels |
GB0814302D0 (en) | 2008-08-05 | 2008-10-01 | Coretherapix Slu | Compounds and methods |
TWI527590B (en) * | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Freeze-dried formulations of fgf-18 |
WO2014024173A2 (en) * | 2012-08-10 | 2014-02-13 | Florida State University Research Foundation | Recombinant human fibroblast growth factor-1 as a novel therapeutic for ischemic diseases and methods thereof |
CN108693179A (en) * | 2018-05-17 | 2018-10-23 | 郑州翱翔医药科技股份有限公司 | A kind of rapid identification method of medicinal butyl rubber bung quality |
KR102283915B1 (en) * | 2019-12-31 | 2021-08-02 | 주식회사 알지프로나 | The vectors for expressing hFGF1 transformed microalgae for expression those growth factors |
KR102273945B1 (en) * | 2019-12-31 | 2021-07-06 | 주식회사 알지프로나 | The vectors for expressing hFGF2 transformed microalgae for expression those growth factors |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4378347A (en) * | 1980-06-30 | 1983-03-29 | Franco Wayne P | Composition for treating the heart for myocardial infarction |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4296100A (en) | 1980-06-30 | 1981-10-20 | Franco Wayne P | Method of treating the heart for myocardial infarction |
US5464774A (en) | 1984-03-05 | 1995-11-07 | The Salk Institute For Biological Studies | Bovine basic fibroblast growth factor |
US5155214A (en) | 1984-03-05 | 1992-10-13 | The Salk Institute For Biological Studies | Basic fibroblast growth factor |
US4956455A (en) * | 1984-03-05 | 1990-09-11 | The Salk Institute For Biological Studies | Bovine fibroblast growth factor |
US5604293A (en) | 1985-09-12 | 1997-02-18 | Scios Inc. | Recombinant human basic fibroblast growth factor |
US5439818A (en) | 1985-09-12 | 1995-08-08 | Scios Nova Inc. | DNA encoding human recombinant basic fibroblast growth factor |
US5238916A (en) | 1987-05-29 | 1993-08-24 | The Trustees Of Columbia University In The City Of New York | Oncogene encoded polypeptide having growth factor activity and methods of use thereof |
US5155217A (en) | 1987-05-29 | 1992-10-13 | The Trustees Of Columbia University In The City Of New York | Ongogene encoding polypeptide having growth factor activity |
US5750659A (en) | 1987-06-16 | 1998-05-12 | New York University | Mammalian growth factor |
KR890701607A (en) | 1987-11-24 | 1989-12-21 | 원본미기재 | Analogs of fibroblast growth factor |
US5108363A (en) * | 1988-02-19 | 1992-04-28 | Gensia Pharmaceuticals, Inc. | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist |
AU614137B2 (en) | 1988-06-06 | 1991-08-22 | Takeda Chemical Industries Ltd. | Stabilized fgf composition and production thereof |
US5352589A (en) | 1988-09-16 | 1994-10-04 | Farmitalia Carlo Erba S.R.L. | Deletion mutant of basic fibroblast growth factor and production thereof |
US5137734A (en) | 1989-03-22 | 1992-08-11 | Dana Farber Cancer Institute | Angiogenic monoglycerides |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
DE69018357T2 (en) * | 1989-10-06 | 1995-09-21 | Takeda Chemical Industries Ltd | Mutein of HST-1 and its production. |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5126323A (en) | 1989-11-16 | 1992-06-30 | Genetics Institute, Inc. | Homogeneous purified k-fgf and compositions containing the same |
US5612211A (en) | 1990-06-08 | 1997-03-18 | New York University | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors |
US5310883A (en) | 1990-11-23 | 1994-05-10 | American Cyanamid Company | Chimeric fibroblast growth factors |
US5206354A (en) | 1990-11-23 | 1993-04-27 | American Cyanamid Company | Dna sequence encoding active fragment of fibroblast growth factor, hbf-2 |
US5213570A (en) | 1990-12-14 | 1993-05-25 | Mallinckrodt Medical, Inc. | System and method for oxygenation of the pericardium |
US5137510A (en) | 1990-12-14 | 1992-08-11 | Mallinckrodt Medical, Inc. | System and method for oxygenation of the heart using subpericardial fluids |
US5269326A (en) | 1991-10-24 | 1993-12-14 | Georgetown University | Method for transvenously accessing the pericardial space via the right auricle for medical procedures |
US5244460A (en) | 1991-11-27 | 1993-09-14 | The United States Of America As Represented By The Department Of Health And Human Services | Method to foster myocardial blood vessel growth and improve blood flow to the heart |
US5491220A (en) | 1993-09-24 | 1996-02-13 | Yeda Research And Development Co., Ltd. | Surface loop structural analogues of fibroblast growth factors |
US20030148968A1 (en) * | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
US5792453A (en) | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
AU1057097A (en) * | 1995-12-22 | 1997-07-17 | Beth Israel Deaconess Medical Center | Localized intravascular delivery of growth factors for promotion of angiogenesis |
ES2293473T3 (en) * | 1998-02-05 | 2008-03-16 | Biosense Webster, Inc. | INTRACARDIAC ADMINISTRATION OF FARMACO. |
DE69941034D1 (en) | 1998-09-03 | 2009-08-06 | Novartis Vaccines & Diagnostic | Fgf-2 angiogenic unit effective dose and method of use |
US20020072489A1 (en) | 1998-10-13 | 2002-06-13 | Whitehouse Martha J. | Angiogenically effective unit dose of FGF-2 and method of use |
JP2002527401A (en) * | 1998-10-13 | 2002-08-27 | カイロン コーポレイション | Angiogenically effective unit dose of FGF and method of administration |
US20030166550A1 (en) | 1999-08-27 | 2003-09-04 | Chiron Corporation | Angiogenically effective unit dose of FGF-2 and method of use |
US6440934B1 (en) | 1998-10-13 | 2002-08-27 | Chiron Corporation | Angiogenically effective unit dose of FGF-2 and method of use |
-
1999
- 1999-10-13 JP JP2000575522A patent/JP2002527401A/en not_active Withdrawn
- 1999-10-13 WO PCT/US1999/022936 patent/WO2000021548A2/en not_active Application Discontinuation
- 1999-10-13 EP EP99951728A patent/EP1121141A2/en not_active Withdrawn
- 1999-10-13 US US09/417,721 patent/US6451303B1/en not_active Expired - Lifetime
- 1999-10-13 AU AU64111/99A patent/AU6411199A/en not_active Abandoned
-
2002
- 2002-04-25 US US10/131,965 patent/US20020165160A1/en not_active Abandoned
-
2005
- 2005-09-29 US US11/238,936 patent/US7511019B2/en not_active Expired - Fee Related
-
2009
- 2009-02-24 US US12/391,956 patent/US7858584B2/en not_active Expired - Fee Related
-
2010
- 2010-02-26 JP JP2010043385A patent/JP2010174017A/en not_active Withdrawn
-
2013
- 2013-05-08 JP JP2013098522A patent/JP2013155193A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4378347A (en) * | 1980-06-30 | 1983-03-29 | Franco Wayne P | Composition for treating the heart for myocardial infarction |
Non-Patent Citations (3)
Title |
---|
FOLKMAN J.: "Angiogenic therapy for the human heart", CIRCULATION, vol. 97, 1998, pages 628 - 629, XP000891914 * |
KIRSCHNER PAMELA B ET AL: "Basic fibroblast growth factor protects against excitotoxicity and chemical hypoxia in both neonatal and adult rats.", JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM 1995, vol. 15, no. 4, 1995, pages 619 - 623, XP000906721, ISSN: 0271-678X * |
SELLKE FRANK W ET AL: "Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.", SURGERY (ST LOUIS) 1996, vol. 120, no. 2, 1996, pages 182 - 188, XP000891931, ISSN: 0039-6060 * |
Also Published As
Publication number | Publication date |
---|---|
JP2013155193A (en) | 2013-08-15 |
EP1121141A2 (en) | 2001-08-08 |
US20060025343A1 (en) | 2006-02-02 |
AU6411199A (en) | 2000-05-01 |
JP2010174017A (en) | 2010-08-12 |
US20020165160A1 (en) | 2002-11-07 |
US20090170776A1 (en) | 2009-07-02 |
WO2000021548A2 (en) | 2000-04-20 |
JP2002527401A (en) | 2002-08-27 |
US7511019B2 (en) | 2009-03-31 |
US7858584B2 (en) | 2010-12-28 |
US6451303B1 (en) | 2002-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000021548A3 (en) | Angiogenically effective unit dose of fgf and method of administering | |
IL135712A (en) | Use of recombinant activated protein c in the manufacture of medicaments for treating or preventing acquired hypercoagulable states associated with sepsis | |
AU2001268680A1 (en) | Methods and compositions for the treatment of peripheral artery disease | |
JP2002527401A5 (en) | ||
UA56989C2 (en) | PHYSIOLOGICALLY ACTIVE PEG-CONJUGATE OF a-INTERFERON, A METHOD FOR PREPARING THE SAME, A PHARMACEUTICAL COMPOSITION BASED THEREON AND A METHOD FOR TREATMENT OR PROPHYLAXIS OF IMMUNOMODULAR DISEASES | |
CA2163112A1 (en) | A coagulation factor viii formulation | |
HK1075409A1 (en) | Angiogenically effective unit dose of fgf-2 and method of use fgf-2 | |
WO1999004772A3 (en) | Use of levobupivacaine | |
AU693833B2 (en) | Products containing G-CSF and TNF binding protein | |
BR9813318A (en) | Process of treating tumors and macular degeneration in a human or veterinary patient, pharmaceutical composition for treating tumors and macular degeneration in a human or veterinary patient | |
WO2002058720A3 (en) | Angiogenically effective unit dose of fgf-2 and method of use | |
EP1304108A3 (en) | Anti-arrhythmic composition and methods of treatment | |
GB9023701D0 (en) | Medical treatment | |
JP2002524420A5 (en) | ||
AU1656997A (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer | |
GR3032224T3 (en) | Therapeutic agent for threatened abortion. | |
WO2004045513A3 (en) | Coronary artery disease treatment | |
WO1998024421A3 (en) | Use of dextrin sulphate for the treatment of highly vascular tumours | |
EP1894570A3 (en) | Methods and compositions for the treatment of peripheral artery disease | |
RU96107031A (en) | METHOD FOR TREATMENT OF GENTINGTON CHOREA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 1999 64111 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 575522 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999951728 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999951728 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999951728 Country of ref document: EP |